Bharat Biotech to produce Coronavirus Vaccine in Odisha Unit

Vaccine and bio-therapeutics giant Bharat Biotech (BBIL), a Hyderabad-based Multi-National Company, has announced the establishment of an exclusive unit in Odisha to manufacture ten variants of vaccines – including that for the novel coronavirus.

In a meeting with Odisha Chief Secretary Asit Tripathy, the company’s Chairman and Managing Director Dr. Krishna Ella said that BBIL was well prepared for the challenge and promised that the latest technology would be implemented in the Odisha unit. “The company has taken up the development and production of new or improved vaccines against severe Rotavirus Diarrhoea, Malaria, Japanese Encephalitis, Rabies, Pandemic Influenza, and drug-resistant Staphylococcus aureus”, Dr. Ella said. The unit, proposed to be set up in Andharua in Bhubaneswar, will see an investment of around ₹300 crores.

Asit Tripathy has assured all support for future expansion plans of the company with respect to the Andharua plant. He has also directed the concerned authority to start preliminary construction work within a fortnight, to facilitate production to begin right away. Tripathy also asked BBIL to set up a state of the art biotechnology incubation centre, common facilities, IT Corridor along with the first phase construction of the industry. Principal Secretary Santosh Sadangi said, “In the meanwhile, the required statutory clearances and pollution control board permission has been availed for setting up the unit”.

The investment made by Bharat Biotech is a key rejoinder to the theme of ‘Make in Odisha’, which is one of Chief Minister Naveen Patnaik’s pet projects. Odisha as a state has become increasingly competitive as a manufacturing hub, with governmental support and ease of policy. The Make-in-Odisha conclave, a one-stop hub to learn about the investment potential of the state, is organised by the government once in every two years. The last edition of the Make in Odisha conclave – held in 2018 – was a resounding success, with the state bagging cumulative investments worth ₹4.19 lakh crores.

The pandemic and the prolonged lockdown has exposed the inherent vulnerabilities of urbanised industrial states. On the contrary, Odisha’s business-friendly policies, political stability and availability of large tracts of non-urbanised land to set up plants act as catalysts for revenue growth of companies that invest. Bharat Biotech’s decision to set up a plant is an ode to the industrialisation efforts and provides a huge fillip to the Make-in-Odisha cause.

Leave a comment